Disclosures for "Comparative Effectiveness of Troriluzole Versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching Methods"
-
Gilbert J. L'Italien has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Gilbert J. L'Italien has stock in biohaven pharmaceuticals.
-
Dr. Potashman has received personal compensation for serving as an employee of Biohaven Pharmaceuticals.
-
Melissa Beiner has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Melissa Beiner has stock in Biohaven Pharmaceuticals.
-
Basia Rogula has received personal compensation for serving as an employee of Broadstreet HEOR.
-
Lauren Powell has nothing to disclose.
-
Victoria Wirtz has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Victoria Wirtz has stock in Biohaven.
-
David Stock has nothing to disclose.
-
Dr. Qureshi has received personal compensation for serving as an employee of Biohaven. Dr. Qureshi has stock in Biohaven Pharmaceuticals.
-
Dr. Kuo has nothing to disclose.
-
Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reata Pharmaceuticals. Dr. Rosenthal has received research support from NIH. Dr. Rosenthal has received research support from Gordon and Marilyn Macklin Foundation. Dr. Rosenthal has received research support from The Daniel B. and Florence E. Green Foundation. Dr. Rosenthal has received research support from National Ataxia Foundation. Dr. Rosenthal has received research support from Michael J. Fox Foundation. Dr. Rosenthal has received research support from Pfizer. Dr. Rosenthal has received research support from Biohaven Pharmaceuticals. Dr. Rosenthal has a non-compensated relationship as a Medical Director, ex-officio Member of the Board with National Ataxia Foundation that is relevant to AAN interests or activities.
-
Dr. Perlman has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Schmahmann has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. The institution of Dr. Schmahmann has received research support from National Ataxia Foundation. The institution of Dr. Schmahmann has received research support from Biohaven. Dr. Schmahmann has received intellectual property interests from a discovery or technology relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care.